Phil Nadeau, Ph.D.

Managing Director, Health Care - Biotechnology

Headshot photo of Phil Nadeau

Philip Nadeau is a managing director and senior research analyst on the biotechnology team at Cowen. He joined Cowen in 2000 and is responsible for covering approximately 25 large-, mid-, and small-cap biotechnology stocks. Cowen’s biotechnology team has consistently been among the top-ranked teams in the Greenwich Survey. Dr. Nadeau has been recognized in The Wall Street Journal’s “Best on the Street” rankings and in the Institutional Investor poll. His views on biotechnology topics are often quoted by national news services such as Reuters, Bloomberg and the Dow Jones newswires. Prior to joining Cowen, he was a research assistant at Children’s Hospital, Boston.

Dr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a Ph.D. in Neurobiology from Harvard University.

Get In Touch

Start a conversation with Phil Nadeau

Insights

Explore related thought leadership, reports, coverage and insights for Phil Nadeau.

Ahead of the Curve®

Investor’s Guide to Immuno-Oncology: Focus on Novel Targets

Read More
Ahead of the Curve®

Trials and Triumphs of Gene Therapy: A Compendium

Read More
Ahead of the Curve®

The ABCs of ADCs: Investor Primer on Antibody Drug Conjugates

Read More

Research Contacts

Our Research team is led by seasoned, entrepreneurial-minded individuals who are driven by a relentless curiosity to redefine expectations.

Meet Our People
Senior businessman handshaking with young woman in the office